A US patent tribunal office has refused Viatris’ requests to invalidate two US semaglutide composition patents, the active ingredient in Novo Nordisk’s renowned Wegovy treatment for obesity among other of the Danish originator’s major brands, raising the potential for generic competition to be pushed out until the early 2030s.
In two separate petitions, Viatris had requested the US Patent and Trademark Office’s Patent Trial Appeal Board to institute an...






